Evidence map›Paper›PMID 23416859›Full record

ReviewClinical advances in hematology & oncology : H&O2013

Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions.

Channing J Paller, Emmanuel S Antonarakis

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in Clinical advances in hematology & oncology : H&O, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04234399 (Determination of the Diagnostic Detection Rate of Axumin), which is not on this map. Cited by 126 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed, 5 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04234399 terminatednot on this mapstarted 2020, after this paper: background citation

Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) PET/CT Utilizing the High Resolution Digital Philips Vereos Scanner, in Patients With Biochemical Recurrence After Radical Prostatectomy

TypeobservationalSponsorUniversity of VermontRan2020 to 2024Enrolled22ConditionsProstatic NeoplasmArmsFluciclovine PET/CT using a digital PET/CT
3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 5 syntheses or guidelines pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. An intra-patient contemporaneous comparison ofEuropean journal of nuclear medicine and molecular imaging · 2026
    Trial
  8. AnCurrent radiopharmaceuticals · 2024
    Trial
  9. Trial
  10. Diagnostic Performance ofClinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  11. Trial
  12. Trial
  13. A Prospective Study onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Trial
  14. European journal of nuclear medicine and molecular imaging · 2019
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Channing J PallerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA.
Emmanuel S Antonarakis
Johns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
NCI NIH HHS P30 CA006973
6 · The paper itself

Abstract

Among men treated with prostatectomy or radiation therapy for localized prostate cancer, the state of an increasing prostate-specific antigen (PSA) level is known as biochemical recurrence (BCR). BCR can be predictive of the development of subsequent distant metastases and ultimately death, but BCR often predates other signs of clinical progression by several years. Although patients may be concerned about their rising PSA levels, physicians attempting to address patient anxiety must inform them that BCR is not typically associated with imminent death from disease, and that the natural history of biochemical progression may be prolonged. Misinterpretation of the significance of early changes in PSA may cause patients to receive androgen deprivation therapy (ADT) prematurely, especially in settings where the disease is unlikely to impact survival. In addition, knowledge of the morbidities associated with ADT (hot flashes, impotence, sarcopenia, metabolic syndrome, bone loss, and increased risk of vascular disease) has accelerated the search for alternative treatment options for these patients. Clinical trials investigating when and how to best use and supplement hormonal therapies in this patient population are under way, as are trials of novel nonhormonal targeted agents, immunotherapies, natural products, and other pharmaceuticals that have been approved by the US Food and Drug Administration (FDA) for other indications. This review will summarize the acceptable standards of care for the management of biochemically recurrent prostate cancer, and will also outline some novel experimental approaches for the treatment of this disease state.

Indexed as

Standard of CareAndrogen AntagonistsHumansMaleNeoplasm Recurrence, LocalPrognosisProstatectomyProstate-Specific AntigenProstatic NeoplasmsVascular Endothelial Growth Factor AAndrogen AntagonistsProstate-Specific AntigenVascular Endothelial Growth Factor A

Identifiers

PMID23416859
PMCPMC3624708
OpenAlexW2149459776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.